Atypical non-enhancing brain metastases from ALK-positive non-small cell lung carcinoma.
1/5 보강
Brain metastases are a frequent complication of advanced non-small cell lung carcinoma (NSCLC), particularly in anaplastic lymphoma kinase (ALK)-positive cases, which show a strong tendency for centra
APA
Solmaz S, Gulsever CI (2026). Atypical non-enhancing brain metastases from ALK-positive non-small cell lung carcinoma.. Neurocirugia, 500758. https://doi.org/10.1016/j.neucie.2026.500758
MLA
Solmaz S, et al.. "Atypical non-enhancing brain metastases from ALK-positive non-small cell lung carcinoma.." Neurocirugia, 2026, pp. 500758.
PMID
41579961 ↗
Abstract 한글 요약
Brain metastases are a frequent complication of advanced non-small cell lung carcinoma (NSCLC), particularly in anaplastic lymphoma kinase (ALK)-positive cases, which show a strong tendency for central nervous system spread. Typically, such metastases demonstrate contrast enhancement on magnetic resonance imaging (MRI) due to disruption of the blood-brain barrier. We report a 45-year-old man with ALK-positive NSCLC presenting with a right temporal swelling and multiple non-contrast-enhancing brain lesions detected before any treatment. The temporal mass was excised and confirmed as metastatic adenocarcinoma. The patient received whole-brain radiotherapy (30Gy in 10 fractions), cisplatin-pemetrexed chemotherapy, and sequential targeted therapy with alectinib and lorlatinib. During three years of follow-up, MRI showed complete resolution of all lesions, and the patient remained neurologically intact and systemically stable. This case underscores the rarity of non-enhancing brain metastases in ALK-positive NSCLC and highlights the importance of recognizing this atypical imaging presentation for timely diagnosis and management.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Unraveling the Enigma of Melanoma Brain Metastasis: New Molecular Insights and Therapeutic Directions.
- Recent advances in systemic treatment for HER2-negative breast cancer with brain metastases.
- Brain radiotherapy added to first-line immunochemotherapy improves survival in patients with treatment-naïve, driver-negative lung adenocarcinoma and synchronous brain metastases.
- Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.
- Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative.
- Opportunities and Challenges of Visual Large Language Models in Imaging Diagnostics: Lessons from Brain Metastasis Detection in Clinical MRI.